이반드로네이트 주사제의 6개월 및 12개월 지속성 : 예비 연구부분

Abstract

Objectives: This study was to evaluate persistence of quarterly intravenous injection of ibandronate and factors relative to persistence. Methods: In this retrospective study, 136 postmenopausal women with osteopenia or osteoporosis who received injections of ibandronate between August 2007 and October 2008 were evaluated for persistence to intravenous ibandronate, reasons for their choice of ibandronate, reasons for stopping medication, acute inflammatory reaction, and other medications after stopping ibandronate by chart review, questionnaire, and telephone interview. Results: Persistence at 6 months and 12 months was 88.1% and 82.8%, respectively. Patients chose ibandronate for reasons of convenience of a quarterly injection, GI trouble, and the inconvenience of oral bisphosphonates, and other medications. Reasons for stopping ibandronate included adverse effects, inconvenience of a direct visit to the hospital at quarterly intervals, cost, and so on. Acute inflammatory reactions were more noticeable in the non-persistent group than in the persistent group, and a previous history of oral bisphosphonate did not affect occurrence of acute inflammatory reactions. Conclusion: Intravenous ibandronate is a good alternative to oral osteoporosis medications due to the convenience for quarterly injection and no GI trouble, and may increase persistence of osteoporosis medication